Navigation Links
Arena Pharmaceuticals Receives Notice from FDA of Advisory Committee Meeting for Lorcaserin
Date:2/1/2012

SAN DIEGO, and WOODCLIFF LAKE, N.J., Feb. 1, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has notified Arena that an Endocrinologic and Metabolic Drugs Advisory Committee meeting to discuss the lorcaserin New Drug Application (NDA) resubmission will be held in the second quarter of 2012. Confirmation and details of the meeting will be published in the Federal Register.

Lorcaserin is an investigational drug candidate intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition. Arena resubmitted the lorcaserin NDA in December 2011, and the FDA assigned a new Prescription Drug User Fee Act (PDUFA) target date of June 27, 2012.

About LorcaserinLorcaserin is a new chemical entity that is believed to act as a selective serotonin 2C receptor agonist. The serotonin 2C receptor is expressed in the brain, including the hypothalamus, an area believed to be involved in the control of appetite and metabolism. Arena has patents that cover lorcaserin in the United States and other jurisdictions that in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States subject to FDA approval of the lorcaserin NDA.

About Arena PharmaceuticalsArena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic are
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... LONDON , Sept. 30, 2014 ... market for molecular imaging informatics solutions including nuclear ... fusion and comparison. The study assesses the size ... between 2010 and 2013, and projects future growth ... well as the dynamics taking place in the ...
(Date:9/30/2014)... , Sept. 30, 2014  Decision Resources Group finds ... Brazil , Russia ... China (BRIC) will see robust expansion as ... favored over surgical procedures. Although revenues will be somewhat ... challenges, prolonged device approval times and demand for low-cost ...
(Date:9/30/2014)...  Alimera Sciences, Inc. (NASDAQ: ALIM ) ... development and commercialization of prescription ophthalmic pharmaceuticals, announced today ... Hercules Technology Growth Capital, Inc. (NYSE: HTGC ... advance under the Loan and Security Agreement that Alimera,s ... Alimera Sciences Limited, entered into with Hercules in April ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2
... CAMBRIDGE, Mass., Dec. 22, 2011  Inspiration Biopharmaceuticals, Inc. ... the development and commercialization of new treatment options ... Company has expanded its leadership team with four ... Inspiration as Chief Medical Officer; Daniel Regan as ...
... Dec. 22, 2011  PTC Therapeutics, Inc. (PTC) today ... Drug Discovery (SDD) Award from the Wellcome Trust ... target life-threatening infections caused by multidrug-resistant (MDR) Gram-negative ... Award from the Wellcome Trust to support its ...
Cached Medicine Technology:Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 2Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 3Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 4Inspiration Biopharmaceuticals Expands Leadership Team with Four New Hires 5PTC Therapeutics' Antibacterial Program Receives $5 Million Award from the Wellcome Trust 2
(Date:9/30/2014)... Children conceived either less than one year or more than ... at increased risk for autism, a new study suggests. ... agree that the research can,t prove that birth spacing has ... important that parents understand that the odds for autism are ... far apart," said outside expert Dr. Andrew Adesman. He is ...
(Date:9/30/2014)... damaging "brain tsunamis" in injured patients without opening ... reality, thanks to pioneering research at the University ... team, led by Jed Hartings, PhD, research associate ... UC College of Medicine, has shown that spreading ... like tsunami wavescan be measured by the placement ...
(Date:9/30/2014)... lung cancer, breast cancer is the leading cause of ... Society. That,s why so many medical professionals encourage women ... at best: only a minority of suspicious mammograms actually ... lots of needless worry for women and their familiesnot ... tests, including ultrasounds and biopsies. , Recently, a ...
(Date:9/30/2014)... Legislation passed in 2003 to slow the spiraling ... to treat Medicare patients has had no meaningful impact ... researchers in the Journal of Clinical Oncology ... outpatient chemotherapy to treat colorectal and lung cancers, and ... prescribe those drugs following the implementation of the recent ...
(Date:9/30/2014)... NJ (PRWEB) September 30, 2014 ... and wellness, is opening another new medical specialty practice ... IMA Cardiology will be located within the ... Ziad Abbud and Dr. Isaac Tawfik of American Heart ... N.J. The new practice will offer Integrated Medicine Alliance ...
Breaking Medicine News(10 mins):Health News:Spacing Between Sibling Births Tied to Autism Risk in Study 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 2Health News:Researchers show EEG's potential to reveal depolarizations following TBI 3Health News:'Virtual breast' could improve cancer detection 2Health News:Landmark Medicare law had little impact on reducing chemotherapy cost 2Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2
... say finding could be key to new disease-fighting therapies ... on mice suggests inhibiting a protein that allows certain ... to cancer-fighting treatments. , A study by Pierre Sonveaux ... found that tumor cells use different fuel sources depending ...
... A team of researchers at Duke University Medical Center and ... acid is an important energy source for tumor cells. In ... most hard-to-kill, dangerous tumor cells by preventing them from delivering ... than 50 years that low-oxygen, or hypoxic, cells cause resistance ...
... MORRISTOWN, N.J., Nov. 20 /PRNewswire/ Bayer HealthCare,has donated hundreds ... New Jersey,(CFBNJ) in response to an urgent call from ... supplies at the state,s food banks. , ... , Mary Lou Panzano, director, US Internal ...
... cancer patients who underwent a mastectomy who undergo ... reconstruction provides fewer long-term complications and better cosmetic ... to a study in the November issue of ... the official journal of the American Society for ...
... Alzheimer,s relatives at risk for hospital visits of their own ... providing care for a loved one with Alzheimer,s results in ... room or hospital visit every six months, says an Indiana ... care of an Alzheimer,s patient is difficult, but the Indiana ...
... Centre Finalizes Construction Plan and Begins Marketing; John Strong, ... Inc., to Lead Sales and Marketing Efforts , ... The world,s first permanent international healthcare marketplace and ... the key players driving the project said today, as ...
Cached Medicine News:Health News:Lactic acid found to fuel tumors 2Health News:Bayer HealthCare Donates Hundreds of Food Items to Community Food Bank of New Jersey in Response to Governor's Plea to Help the State's Population in Need 2Health News:Type of breast reconstruction impacts radiation therapy outcomes 2Health News:When the Caregiver Becomes the Patient 2Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 2Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 3Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 4Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 5
The 45 PSI SuperSportNeb provides superior performance that translates to shorter treatment times. Like the SportNeb, it is constructed with die-cast aluminum compressor components for consistent rel...
... PulmoAide Compact Compressor provides effective therapy at an ... therapy at home or on the go and ... the same reliable operation you have come to ... Compressor is the perfect solution for those patients ...
The 16 liter Laparoscopy Insufflator combines high safety and precise pressure control with simple operation....
Stryker's 40-liter insufflator provides superior performance with unprecedented safety and reliability....
Medicine Products: